Determining the effects of increased demands for voluntary adjustments on the neuromuscular control of walking post-stroke

确定自愿调整需求增加对中风后行走神经肌肉控制的影响

基本信息

  • 批准号:
    10596397
  • 负责人:
  • 金额:
    $ 15.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Abstract The goal of this proposal is to determine the effects of explicitly driven or implicitly driven walking modifications on muscle activation patterns and co-contraction post-stroke. This work is significant, as studies have shown that muscle activation patterns after neurologic injury cannot generate walking kinematics comparable to those seen in neurotypical individuals; this finding implies that to attain true walking recovery after neurologic injury, interventions should aim to restore the muscle activations underlying walking behaviors. Here, we first explore muscle activations during walking using biofeedback to guide explicit modification of walking patterns, which is a common approach used in clinical and research interventions for walking retraining. We hypothesize that explicit walking modifications might be detrimental at a muscle activation level as they engage cortical pathways for voluntary control that have been interrupted by the stroke lesion, resulting in increased muscle co-contraction. Co-contraction hinders true recovery as it impairs the ability to selectively control different segments during walking, resulting in overreliance on compensatory patterns. We will also explore muscle activation patterns during implicit walking modifications. We will use external modifications in the walking environment, mainly split-belt adaptation followed by tied belt walking, to assess if implicit modifications of walking that rely less on cortical neural control are associated with levels of co-contraction comparable to neurotypical controls—an indication that implicitly-mediated modifications could be a more effective approach to restore muscle activation patterns during walking post-stroke. In this study, we will assess co-contraction during walking in people post-stroke as they reduce asymmetry in step lengths guided by explicit biofeedback (Aim 1) or implicitly following split-belt adaptation and washout (Aim 2). Our central hypothesis is that given differences in the neural control of explicitly- vs. implicitly-mediated walking modifications, we will observe greater levels of co-contraction with interventions that rely on explicit compared to implicit control. Supplementing this central hypothesis, we also predict that co-contraction will be associated with motor impairment, and in more impaired individuals co-contraction will be exacerbated by explicit modifications given the reliance on lesioned cortical pathways. Our results will identify the tasks and conditions that can reduce co- contraction to promote restoration of neuromuscular control post-stroke. This proposal aligns with the NCMRR research priority to develop objective markers of treatment response and functional progress that predict rehabilitation treatment response and enable the tailoring of interventions to the needs, abilities, and resources of the person with disability.
摘要 这个建议的目标是确定显式驱动或隐式驱动的步行修改的效果 中风后的肌肉激活模式和协同收缩。研究表明,这项工作意义重大 神经损伤后的肌肉激活模式不能产生与那些 在神经典型个体中可见;这一发现意味着为了在神经损伤后获得真正的行走恢复, 干预措施应旨在恢复步行行为背后的肌肉激活。在这里,我们首先探索 在步行过程中使用生物反馈来指导明确修改步行模式,这是 这是临床和研究干预中用于行走再训练的常用方法。我们假设 明确的步行改变可能在肌肉激活水平上是有害的,因为它们涉及皮层神经元, 自愿控制的途径已被中风病变中断,导致肌肉增加 共收缩。共同收缩阻碍了真正的复苏,因为它损害了选择性控制不同的能力。 在步行过程中的节,导致过度依赖代偿模式。我们还将探索肌肉 在隐式步行修改期间的激活模式。我们将在行走中使用外部修改 环境,主要是分裂带适应,然后是系带行走,以评估是否隐含的修改, 较少依赖皮质神经控制的行走与协同收缩水平相关, 神经典型对照-暗示介导的修饰可能是更有效的方法 恢复中风后行走时的肌肉激活模式。在这项研究中,我们将评估共同收缩 在中风后的人行走过程中,由于他们在明确的生物反馈指导下减少了步长的不对称性, (Aim 1)或隐含地遵循分裂带适应和洗脱(目标2)。我们的核心假设是, 显式与隐式介导的步行修改的神经控制的差异,我们将观察 与内隐控制相比,依赖外显控制的干预措施的共同收缩程度更高。 补充这一中心假设,我们还预测,共同收缩将与运动 在更多受损的个体中,共同收缩将因明确的修改而加剧, 对受损皮层通路的依赖我们的研究结果将确定任务和条件,可以减少co- 收缩以促进中风后神经肌肉控制的恢复。本提案与NCMRR保持一致 优先研究开发治疗反应和功能进展的客观标志物, 康复治疗反应,并使干预措施能够适应需求,能力和资源 残疾人的权利。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Natalia Sanchez其他文献

Natalia Sanchez的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Natalia Sanchez', 18)}}的其他基金

A precision medicine approach to identify walking phenotypes and rehabilitation targets after injury
一种识别步行表型和受伤后康复目标的精准医学方法
  • 批准号:
    10662525
  • 财政年份:
    2022
  • 资助金额:
    $ 15.16万
  • 项目类别:
A precision medicine approach to identify walking phenotypes and rehabilitation targets after injury
一种识别步行表型和受伤后康复目标的精准医学方法
  • 批准号:
    10735699
  • 财政年份:
    2022
  • 资助金额:
    $ 15.16万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 15.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 15.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 15.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了